BioengineeringbioRxiv
Stable nebulization and muco-trapping properties of Regdanvimab/IN-006 support its development as a potent, dose-saving inhaled therapy for COVID-19
M. D. McSweeney, I. Stewart, Z. Richardson…·S. K. Lai
This paper demonstrates that IN-006, a reformulated Regdanvimab, effectively traps SARS-CoV-2 virus-like particles in human airway mucus and achieves higher lung concentrations in rats when nebulized compared to intravenous delivery.